Literature DB >> 16806857

Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs.

Francesca Ungaro1, Giuseppe De Rosa, Agnese Miro, Fabiana Quaglia, Maria Immacolata La Rotonda.   

Abstract

The aim of this work was to develop dry powders intended for insulin pulmonary delivery. To this purpose, large porous particles (LPP) made of poly(lactide-co-glycolide) (PLGA) were produced by the double emulsion-solvent evaporation technique. Hydroxypropyl-beta-cyclodextrin (HPbetaCD), also known as absorption enhancer for pulmonary protein delivery, was tested as aid excipient to optimize the aerodynamic behaviour of the microparticles. Several microsphere formulations, differing in HPbetaCD and insulin loadings, were produced and their properties compared. A contemporary release of insulin and HPbetaCD from the system can be achieved by selecting appropriate formulation conditions. HPbetaCD-containing LPP with flow properties and dimensions suitable for aerosolization and deposition in deep regions of the lung following inhalation were produced. In conclusion, the developed system turns to be of great potential for the combined delivery of the protein and the adsorption promoter in the respiratory tract.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806857     DOI: 10.1016/j.ejps.2006.05.005

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  18 in total

1.  Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles.

Authors:  Yan-Zhen Li; Xun Sun; Tao Gong; Jie Liu; Jiao Zuo; Zhi-Rong Zhang
Journal:  Pharm Res       Date:  2010-07-13       Impact factor: 4.200

2.  Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study.

Authors:  Sonali R Naikwade; Amrita N Bajaj; Prashant Gurav; Madhumanjiri M Gatne; Pritam Singh Soni
Journal:  AAPS PharmSciTech       Date:  2009-08-01       Impact factor: 3.246

3.  Development of high efficiency ventilation bag actuated dry powder inhalers.

Authors:  Srinivas R B Behara; P Worth Longest; Dale R Farkas; Michael Hindle
Journal:  Int J Pharm       Date:  2014-02-07       Impact factor: 5.875

4.  Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles.

Authors:  Chandan Thomas; Vivek Gupta; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2010-03-16       Impact factor: 4.200

5.  Aerosolized montelukast polymeric particles-an alternative to oral montelukast-alleviate symptoms of asthma in a rodent model.

Authors:  Brijeshkumar Patel; Nilesh Gupta; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2014-06-17       Impact factor: 4.200

6.  Nanocomposite microparticles (nCmP) for the delivery of tacrolimus in the treatment of pulmonary arterial hypertension.

Authors:  Zimeng Wang; Julie L Cuddigan; Sweta K Gupta; Samantha A Meenach
Journal:  Int J Pharm       Date:  2016-08-26       Impact factor: 5.875

7.  Influence of suspension stabilisers on the delivery of protein-loaded porous poly (DL-lactide-co-glycolide) (PLGA) microparticles via pressurised metered dose inhaler (pMDI).

Authors:  Elizabeth Cocks; Satyanarayana Somavarapu; Oya Alpar; David Greenleaf
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

8.  Synthesis and Characterization of Nanocomposite Microparticles (nCmP) for the Treatment of Cystic Fibrosis-Related Infections.

Authors:  Zimeng Wang; Samantha A Meenach
Journal:  Pharm Res       Date:  2016-04-18       Impact factor: 4.200

9.  Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation.

Authors:  Amit Rawat; Quamrul H Majumder; Fakhrul Ahsan
Journal:  J Control Release       Date:  2008-03-21       Impact factor: 9.776

10.  Improving the stability of insulin in solutions containing intestinal proteases in vitro.

Authors:  Liefeng Zhang; Hui Jiang; Wenjie Zhu; Lin Wu; Lingling Song; Qiuyan Wu; Yong Ren
Journal:  Int J Mol Sci       Date:  2008-12-01       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.